Avanos Medical, Inc.
NYSE:AVNSMedical - Devices
+$0.06 today
- Market cap
- $1.17B
- Beta
- 1.57
- P/E (TTM)
- -16.7
- EPS (TTM)
- -$1.50
Volume 0.43M
Average 1.49M
AVNS Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Avanos Medical, Inc.NYSE: AVNS
Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026
Capital expenditures dips below year-ago levels
Q1 FY2026 capital expenditures of $4.3M (cash outflow) fell 35.8% year over year, behind the +43.1% change in trailing-twelve-month capital expenditures. Sequentially, it fell 37.7% from the prior quarter. Over 3 fiscal years it compounded at +17.9% a year.
Context
- Capital expenditures amounted to 4.5% of revenue in FY2025, up 1.9 pp from a year earlier.
- Capital expenditures grew in size in 1 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -35.8% toward the trailing-twelve-month pace of +43.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (31.6M) USD
- Year-over-year change
- -77.5%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (31.6M) | -77.5% |
| FY2024 | 2024-12-31 | (17.8M) | +0.0% |
| FY2023 | 2023-12-31 | (17.8M) | +7.8% |
| FY2022 | 2022-12-31 | (19.3M) | +8.1% |
| FY2021 | 2021-12-31 | (21M) | — |
Capital Expenditures vs competitors
How AVNS compares with its peers on the latest reported figures
- AVNS's LTM Mar 2026 capital expenditures of $29.2M is the 2nd largest of the 11 companies compared; the peer median is $3.06M.
- Its year-over-year change of +43.1% is the 4th highest of 11, against a peer median of -28.6%.
- Capital expenditures amounts to 4.1% of revenue for AVNS, versus a peer median of 2.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $326M | -7.4% | -6.9% | 1.5% | |
| LTM Mar 2026 | $29.2M | +43.1% | +17.9% | 4.1% | |
| LTM Apr 2026 | $28.8M | +32.7% | +2.4% | 3.4% | |
| LTM Mar 2026 | $5.4M | +43.5% | -25.5% | 2.6% | |
| LTM Mar 2026 | $4.37M | -49.8% | -45.7% | 2.7% | |
| LTM Mar 2026 | $3.82M | -69.8% | +29.5% | 4.4% | |
| LTM Mar 2026 | $2.31M | +49.9% | +20.1% | 0.4% | |
| LTM Mar 2026 | $984K | +114.8% | +27.3% | 2.4% | |
CBLLCeriBell, Inc. | LTM Mar 2026 | $744K | -50.0% | +14.1% | 0.8% |
| LTM Mar 2026 | $606K | -83.7% | -64.0% | 0.7% | |
| LTM Mar 2026 | $106.68K | -94.2% | -50.1% | 0.2% | |
| Peer median (excluding AVNS) | $3.06M | -28.6% | -2.2% | 2.0% | |
Competitors are the stored peer set for AVNS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 5.2M | 50.5M | (61.8M) | (392.1M) | (72.9M) |
| Depreciation & Amortization | 38.3M | 47.7M | 46.1M | 45.5M | 38.9M |
| Deferred Income Tax | (3.4M) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 13.2M | 15.9M | 15.8M | 13.8M | 12.6M |
| Change in Working Capital | 26M | (24.3M) | (18M) | 35M | 9.8M |
| Accounts Receivables | (10.8M) | (24.7M) | 39M | (6.6M) | 30.9M |
| Inventory | 17.2M | (30.9M) | 4.7M | 39M | 200K |
| Accounts Payables | (11.9M) | 35.4M | (14.4M) | (900K) | 600K |
| Other Working Capital | 31.5M | (4.1M) | (47.3M) | 3.5M | (21.9M) |
| Other Non-Cash Items | 8M | 1.1M | 50.3M | 398.5M | 86.3M |
| Operating Cash Flow | 87.3M | 90.9M | 32.4M | 100.7M | 74.7M |
| Capital Expenditures | (21M) | (19.3M) | (17.8M) | (17.8M) | (31.6M) |
| Acquisitions (Net) | 0 | (116.1M) | 39.4M | (9.7M) | (28M) |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | (1M) |
| Investing Cash Flow | (21M) | (135.4M) | 21.6M | (27.5M) | (60.6M) |
| Debt Repayment | (50M) | 103.4M | (64.7M) | (33.6M) | (34.4M) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 700K |
| Common Stock Repurchased | (11.5M) | (45.5M) | (19.1M) | (12.8M) | (3.3M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 6.2M | (1.2M) | (10.4M) | (2.7M) | 0 |
| Financing Cash Flow | (55.3M) | 56.7M | (94.2M) | (49.1M) | (37M) |
| Effect of Forex Changes | (4M) | (3M) | 200K | (4.1M) | 5M |
| Net Change in Cash | 7M | 9.2M | (40M) | 20M | (17.9M) |
| Free Cash Flow | 66.3M | 71.6M | 14.6M | 82.9M | 43.1M |
Avanos Medical, Inc.
NYSE:AVNS
Intrinsic Alpha fair value
Locked
Current Price
$24.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.